| 1 |
Peters SL, Gibson PR, Halmos EP. Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: A retrospective evaluation. Neurogastroenterol Motil 2023;35:e14533. [PMID: 36661117 DOI: 10.1111/nmo.14533] [Reference Citation Analysis]
|
| 2 |
Knowles SR, Skvarc D, Ford AC, Palsson OS, Bangdiwala SI, Sperber AD, Mikocka-Walus A. Negative Impact of Disorders of Gut-Brain Interaction on Health-Related Quality of Life: Results From the Rome Foundation Global Epidemiology Survey. Gastroenterology 2023;164:655-668.e10. [PMID: 36565940 DOI: 10.1053/j.gastro.2022.12.009] [Reference Citation Analysis]
|
| 3 |
Hasan SS, Ballou S, Keefer L, Vasant DH. Improving access to gut-directed hypnotherapy for irritable bowel syndrome in the digital therapeutics' era: Are mobile applications a "smart" solution? Neurogastroenterol Motil 2023;35:e14554. [PMID: 36847206 DOI: 10.1111/nmo.14554] [Reference Citation Analysis]
|
| 4 |
Lu L, Liu C, Liu K, Shi C, Liu Z, Jiang X, Wang F. The causal effects of leisure screen time on irritable bowel syndrome risk: result from a Mendelian randomization study.. [DOI: 10.21203/rs.3.rs-2639416/v1] [Reference Citation Analysis]
|
| 5 |
Goodoory VC, Ng CE, Black CJ, Ford AC. Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome. Aliment Pharmacol Ther 2023. [PMID: 36914979 DOI: 10.1111/apt.17465] [Reference Citation Analysis]
|
| 6 |
Camilleri M, Boeckxstaens G. Irritable bowel syndrome: treatment based on pathophysiology and biomarkers. Gut 2023;72:590-9. [PMID: 36307180 DOI: 10.1136/gutjnl-2022-328515] [Reference Citation Analysis]
|
| 7 |
So D, Quigley EMM, Whelan K. Probiotics in irritable bowel syndrome and inflammatory bowel disease: review of mechanisms and effectiveness. Curr Opin Gastroenterol 2023;39:103-9. [PMID: 36821458 DOI: 10.1097/MOG.0000000000000902] [Reference Citation Analysis]
|
| 8 |
Rodrigues T, Rodrigues Fialho S, Araújo JR, Rocha R, Moreira-Rosário A. Procedures in Fecal Microbiota Transplantation for Treating Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. J Clin Med 2023;12. [PMID: 36902512 DOI: 10.3390/jcm12051725] [Reference Citation Analysis]
|
| 9 |
Zhang VR, Ramachandran GK, Loo EXL, Soh AYS, Yong WP, Siah KTH. Volatile organic compounds as potential biomarkers of irritable bowel syndrome: A systematic review. Neurogastroenterol Motil 2023;:e14536. [PMID: 36780514 DOI: 10.1111/nmo.14536] [Reference Citation Analysis]
|
| 10 |
Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther 2023;57:323-34. [PMID: 36544055 DOI: 10.1111/apt.17356] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F, Fuccio L, Galeazzi F, Iovino P, Sarnelli G, Savarino EV, Stanghellini V, Staiano A, Stasi C, Tosetti C, Turco R, Ubaldi E, Zagari RM, Zenzeri L, Marasco G. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis 2023;55:187-207. [PMID: 36517261 DOI: 10.1016/j.dld.2022.11.015] [Reference Citation Analysis]
|
| 12 |
Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome. Neurogastroenterol Motil 2023;35:e14483. [PMID: 36178331 DOI: 10.1111/nmo.14483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Wu J, Wang C, Lv L. Diagnostic yield of colonoscopy for organic disease in irritable bowel syndrome and its risk factors: A meta-analysis. Neurogastroenterol Motil 2023;35:e14481. [PMID: 36168183 DOI: 10.1111/nmo.14481] [Reference Citation Analysis]
|
| 14 |
Marasco G, Stanghellini V, Barbara G, Cremon C. Gut Microbiota Characterization in Fecal Incontinence and Irritable Bowel Syndrome. Anal Incontinence 2023. [DOI: 10.1007/978-3-031-08392-1_19] [Reference Citation Analysis]
|
| 15 |
Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2023;57:81-93. [PMID: 36369645 DOI: 10.1111/apt.17310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Bravo-Vázquez LA, Medina-Ríos I, Márquez-Gallardo LD, Reyes-Muñoz J, Serrano-Cano FI, Pathak S, Banerjee A, Bandyopadhyay A, Duttaroy AK, Paul S. Functional Implications and Clinical Potential of MicroRNAs in Irritable Bowel Syndrome: A Concise Review. Dig Dis Sci 2023;68:38-53. [PMID: 35507132 DOI: 10.1007/s10620-022-07516-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Bednarska O, Biskou O, Israelsen H, Winberg ME, Walter S, Keita ÅV. A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndrome. Front Nutr 2022;9:1004084. [PMID: 36570171 DOI: 10.3389/fnut.2022.1004084] [Reference Citation Analysis]
|
| 18 |
Bozomitu L, Miron I, Adam Raileanu A, Lupu A, Paduraru G, Marcu FM, Buga AML, Rusu DC, Dragan F, Lupu VV. The Gut Microbiome and Its Implication in the Mucosal Digestive Disorders. Biomedicines 2022;10. [PMID: 36551874 DOI: 10.3390/biomedicines10123117] [Reference Citation Analysis]
|
| 19 |
Rej A, Sanders DS, Shaw CC, Buckle R, Trott N, Agrawal A, Aziz I. Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet. Clin Gastroenterol Hepatol 2022;20:2876-2887.e15. [PMID: 35240330 DOI: 10.1016/j.cgh.2022.02.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 20 |
Howell CA, Kemppinen A, Allgar V, Dodd M, Knowles CH, McLaughlin J, Pandya P, Whorwell P, Markaryan E, Yiannakou Y. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut 2022;71:2430-8. [PMID: 35760493 DOI: 10.1136/gutjnl-2022-327293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Roca JJM, Muñoz RC. Microbiota intestinal. FMC - Formación Médica Continuada en Atención Primaria 2022;29:575-578. [DOI: 10.1016/j.fmc.2022.03.009] [Reference Citation Analysis]
|
| 22 |
Sanz Morales P, Wijeyesekera A, Robertson MD, Jackson PPJ, Gibson GR. The Potential Role of Human Milk Oligosaccharides in Irritable Bowel Syndrome. Microorganisms 2022;10. [PMID: 36557589 DOI: 10.3390/microorganisms10122338] [Reference Citation Analysis]
|
| 23 |
Liu F, Shen Y, Li J, Bi L, Ye X, Li Y, Zhi D. Characteristics of ginsenoside Rd-induced effects on rat intestinal contractility with irritable bowel syndrome. Natural Product Research 2022. [DOI: 10.1080/14786419.2022.2146686] [Reference Citation Analysis]
|
| 24 |
Brenner DM, Lacy BE, Ford AC, Bartolini W, Wu J, Shea EP, Bochenek W, Boinpally R, Almansa C. Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials. Am J Gastroenterol 2022. [PMID: 36227782 DOI: 10.14309/ajg.0000000000002064] [Reference Citation Analysis]
|
| 25 |
Noble H, Hasan SS, Simpson V, Whorwell PJ, Vasant DH. Patient satisfaction after remotely delivered gut-directed hypnotherapy for irritable bowel syndrome during the COVID-19 era: implications for future practice. BMJ Open Gastroenterol 2022;9:e001039. [DOI: 10.1136/bmjgast-2022-001039] [Reference Citation Analysis]
|
| 26 |
Meng YY, Wang EK, Wang YS, Feng Y, Hang L, Yuan JY. Progress in traditional Chinese medicine study of constipation predominant irritable bowel syndrome. Shijie Huaren Xiaohua Zazhi 2022; 30(20): 892-896 [DOI: 10.11569/wcjd.v30.i20.892] [Reference Citation Analysis]
|
| 27 |
Ricci C, Rizzello F, Valerii MC, Spisni E, Gionchetti P, Turroni S, Candela M, D'Amico F, Spigarelli R, Bellocchio I, Marasco G, Barbara G. Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial. Nutrients 2022;14:4208. [PMID: 36235860 DOI: 10.3390/nu14194208] [Reference Citation Analysis]
|
| 28 |
Costantino A, Aversano GM, Lasagni G, Smania V, Doneda L, Vecchi M, Roncoroni L, Pastorello EA, Elli L. Diagnostic management of patients reporting symptoms after wheat ingestion. Front Nutr 2022;9:1007007. [PMID: 36276818 DOI: 10.3389/fnut.2022.1007007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 29 |
Lawton T. Trust your gut: The human microbiome. InnovAiT: Education and inspiration for general practice 2022;15:567-572. [DOI: 10.1177/17557380221111552] [Reference Citation Analysis]
|
| 30 |
Wu P, Xiong S, Zhong P, Yang W, Chen M, Tang T. Global trends in research on irritable bowel syndrome and the brain–gut axis: Bibliometrics and visualization analysis. Front Pharmacol 2022;13:956204. [DOI: 10.3389/fphar.2022.956204] [Reference Citation Analysis]
|
| 31 |
Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther 2022;56:844-56. [PMID: 35794733 DOI: 10.1111/apt.17132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 32 |
Black CJ, Paine PA, Agrawal A, Aziz I, Eugenicos MP, Houghton LA, Hungin P, Overshott R, Vasant DH, Rudd S, Winning RC, Corsetti M, Ford AC. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut 2022;71:1697-723. [PMID: 35798375 DOI: 10.1136/gutjnl-2022-327737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 33 |
Huang Z, Lin Z, Lin C, Chu H, Zheng X, Chen B, Du L, Chen JDZ, Dai N. Transcutaneous Electrical Acustimulation Improves Irritable Bowel Syndrome With Constipation by Accelerating Colon Transit and Reducing Rectal Sensation Using Autonomic Mechanisms. Am J Gastroenterol 2022;117:1491-501. [PMID: 35973183 DOI: 10.14309/ajg.0000000000001882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 34 |
Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther 2022;56:932-41. [PMID: 35942669 DOI: 10.1111/apt.17179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 35 |
Łoniewski I, Skonieczna-żydecka K, Sołek-pastuszka J, Marlicz W. Probiotics in the Management of Mental and Gastrointestinal Post-COVID Symptomes. JCM 2022;11:5155. [DOI: 10.3390/jcm11175155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Liu A, Gao W, Zhu Y, Hou X, Chu H. Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome. Toxins 2022;14:596. [DOI: 10.3390/toxins14090596] [Reference Citation Analysis]
|
| 37 |
Wielgosz-grochowska JP, Domanski N, Drywień ME. Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review. Nutrients 2022;14:3382. [DOI: 10.3390/nu14163382] [Reference Citation Analysis]
|
| 38 |
Bao W, Qi L, Bao Y, Wang S, Li W. Alleviating insomnia should decrease the risk of irritable bowel syndrome: Evidence from Mendelian randomization. Front Pharmacol 2022;13:900788. [DOI: 10.3389/fphar.2022.900788] [Reference Citation Analysis]
|
| 39 |
Young E, Rojas Vasquez LS, Lim A, Philpott H. Low FODMAP diet for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014029] [Reference Citation Analysis]
|
| 40 |
Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, Imaeda H. Update on gut microbiota in gastrointestinal diseases. WJCC 2022;10:7653-64. [DOI: 10.12998/wjcc.v10.i22.7653] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 41 |
Lu Q, Tan D, Luo J, Ye Y, Zuo M, Wang S, Li C. Potential of natural products in the treatment of irritable bowel syndrome. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.154419] [Reference Citation Analysis]
|
| 42 |
Moshiree B, Heidelbaugh JJ, Sayuk GS. A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers. Adv Ther. [DOI: 10.1007/s12325-022-02224-z] [Reference Citation Analysis]
|
| 43 |
Ahmed JF, Padam P, Ruban A. Aetiology, diagnosis and management of small intestinal bacterial overgrowth. Frontline Gastroenterol 2023;14:149-54. [PMID: 36818787 DOI: 10.1136/flgastro-2022-102163] [Reference Citation Analysis]
|
| 44 |
Bellini M, Tosetti C, Rettura F, Morganti R, Lambiase C, Bassotti G, Visaggi P, Pancetti A, Benedetto E, de Bortoli N, Usai-Satta P, De Bastiani R. Translational Gap between Guidelines and Clinical Medicine: The Viewpoint of Italian General Practitioners in the Management of IBS. J Clin Med 2022;11. [PMID: 35807145 DOI: 10.3390/jcm11133861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 45 |
Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther 2022;56:110-20. [PMID: 35491477 DOI: 10.1111/apt.16939] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 46 |
Vasant DH. Burden of persistent symptoms in treated coeliac disease: cause, aftermath or merely association? BMJ Open Gastroenterol 2022;9:e000970. [PMID: 35820710 DOI: 10.1136/bmjgast-2022-000970] [Reference Citation Analysis]
|
| 47 |
Tan ZE, Tan YQ, Lin H, How CH. Irritable bowel syndrome: an approach for primary care physicians. Singapore Med J 2022;63:367-70. [PMID: 36074566 DOI: 10.4103/0037-5675.354224] [Reference Citation Analysis]
|
| 48 |
Siah KTH, Mahadeva S. Hypnotherapy and IBS : Time to take control of the Asian gut. JGH Open 2022;6:445-446. [DOI: 10.1002/jgh3.12785] [Reference Citation Analysis]
|
| 49 |
Mazzawi T. Gut Microbiota Manipulation in Irritable Bowel Syndrome. Microorganisms 2022;10:1332. [DOI: 10.3390/microorganisms10071332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 50 |
Rej A, Sanders DS, Aziz I. Further research needed to determine first-line therapy for IBS in primary care. Gut 2022:gutjnl-2022-328047. [PMID: 35732423 DOI: 10.1136/gutjnl-2022-328047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 51 |
So D, Loughman A, Staudacher HM. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Am J Clin Nutr 2022;116:943-52. [PMID: 35728042 DOI: 10.1093/ajcn/nqac176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 52 |
van Megen F, Skodje GI, Veierød MB, Lundin KEA, Henriksen C. Vedvarende symptomer hos behandlede cøliakipasienter og effekt av moderat lav FODMAP-diett. NTFE 2022;20:28-35. [DOI: 10.18261/ntfe.20.2.6] [Reference Citation Analysis]
|
| 53 |
Lam C, Amarasinghe G, Zarate-Lopez N, Fikree A, Byrne P, Kiani-Alikhan S, Gabe S, Paine P. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterol 2023;14:68-77. [PMID: 36561778 DOI: 10.1136/flgastro-2022-102088] [Reference Citation Analysis]
|
| 54 |
Barberio B, Savarino EV, Black CJ, Ford AC. Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. Neurogastroenterol Motil 2022;34:e14279. [PMID: 34672052 DOI: 10.1111/nmo.14279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 55 |
Goodoory VC, Craig OF, Gracie DJ, Black CJ, Ford AC. Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. Neurogastroenterol Motil 2022;34:e14282. [PMID: 34612560 DOI: 10.1111/nmo.14282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Zhao C, Zhang X, Chen G, Shang L. Developing sensor materials for screening intestinal diseases. Mater Futures 2022;1:022401. [DOI: 10.1088/2752-5724/ac48a3] [Reference Citation Analysis]
|
| 57 |
Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut 2022;71:1117-26. [PMID: 34376515 DOI: 10.1136/gutjnl-2021-325214] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 58 |
Goodoory VC, Ng CE, Black CJ, Ford AC. Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply. Aliment Pharmacol Ther 2022;55:1590-1. [PMID: 35610938 DOI: 10.1111/apt.16966] [Reference Citation Analysis]
|
| 59 |
Sasegbon A, Hasan SS, Whorwell PJ, Vasant DH. Experience and clinical efficacy of gut‐directed hypnotherapy in an Asian population with refractory irritable bowel syndrome. JGH Open. [DOI: 10.1002/jgh3.12770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Ochoa KC, Samant S, Liu A, Duysburgh C, Marzorati M, Singh P, Hachuel D, Chey W, Wallach T. In-Vitro Efficacy of Targeted FODMAP Enzymatic Digestion (FODZYME®) in a High-Fidelity Simulated Gastrointestinal Environment.. [DOI: 10.1101/2022.05.16.492152] [Reference Citation Analysis]
|
| 61 |
Fernández-bañares F. Carbohydrate Maldigestion and Intolerance. Nutrients 2022;14:1923. [DOI: 10.3390/nu14091923] [Reference Citation Analysis]
|
| 62 |
Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Aliment Pharmacol Ther 2022;55:1311-9. [PMID: 35166374 DOI: 10.1111/apt.16816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 63 |
Iovino P, Neri MC, D'Alba L, Santonicola A, Chiarioni G. Pelvic floor biofeedback is an effective treatment for severe bloating in disorders of gut-brain interaction with outlet dysfunction. Neurogastroenterol Motil 2022;34:e14264. [PMID: 34532928 DOI: 10.1111/nmo.14264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Zhang T, Zhang C, Zhang J, Sun F, Duan L. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front Cell Infect Microbiol 2022;12:859967. [DOI: 10.3389/fcimb.2022.859967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 65 |
Gibson PR, Halmos EP, So D, Yao CK, Varney JE, Muir JG. Diet as a therapeutic tool in chronic gastrointestinal disorders: Lessons from the FODMAP journey. J Gastroenterol Hepatol 2022;37:644-52. [PMID: 34994019 DOI: 10.1111/jgh.15772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 66 |
Chen J, Zhang Y, Barandouzi ZA, Lee J, Zhao T, Xu W, Chen M, Feng B, Starkweather A, Cong X. The effect of self-management online modules plus nurse-led support on pain and quality of life among young adults with irritable bowel syndrome: a randomized controlled trial. International Journal of Nursing Studies 2022. [DOI: 10.1016/j.ijnurstu.2022.104278] [Reference Citation Analysis]
|
| 67 |
Sankararaman S, Velayuthan S, Chen Y, Robertson J, Sferra TJ. Role of Traditional Chinese Herbal Medicines in Functional Gastrointestinal and Motility Disorders. Curr Gastroenterol Rep 2022. [PMID: 35353338 DOI: 10.1007/s11894-022-00843-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 68 |
Blad N, Palmqvist R, Karling P. Pre-diagnostic faecal calprotectin levels in patients with colorectal cancer: a retrospective study. BMC Cancer 2022;22:315. [PMID: 35331198 DOI: 10.1186/s12885-022-09440-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
Tao E, Zhu Z, Hu C, Long G, Chen B, Guo R, Fang M, Jiang M. Potential Roles of Enterochromaffin Cells in Early Life Stress-Induced Irritable Bowel Syndrome. Front Cell Neurosci 2022;16:837166. [DOI: 10.3389/fncel.2022.837166] [Reference Citation Analysis]
|
| 70 |
Noble H, Hasan SS, Whorwell PJ, Vasant DH. The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID-19 pandemic. Neurogastroenterol Motil 2022;34:e14347. [PMID: 35238428 DOI: 10.1111/nmo.14347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 71 |
Kramer S, Masclee AAM, Jebbink RJA, Tack GJ. Commonly used biomarkers do not contribute to diagnosing irritable bowel syndrome. Eur J Gastroenterol Hepatol 2022;34:302-7. [PMID: 34775459 DOI: 10.1097/MEG.0000000000002312] [Reference Citation Analysis]
|
| 72 |
Chen J, Zhang Y, Barandouzi ZA, Lee J, Zhao T, Xu W, Chen M, Feng B, Starkweather A, Cong X. The effect of self-management online modules plus nurse-led support on pain and quality of life among young adults with irritable bowel syndrome: A randomized controlled trial.. [DOI: 10.1101/2022.02.23.22271431] [Reference Citation Analysis]
|
| 73 |
Adriani A. Clinical key advances in non-pharmacological treatments for irritable bowel syndrome. Gazz Med Ital - Arch Sci Med 2021;180. [DOI: 10.23736/s0393-3660.21.04699-4] [Reference Citation Analysis]
|
| 74 |
Marlicz W, Skonieczna-Żydecka K, Krynicka P, Łoniewski I, Rydzewska G. Probiotics in irritable bowel syndrome - is the quest for the right strain over? Rapid review of existing guidelines and recommendations. Prz Gastroenterol 2021;16:369-82. [PMID: 34976247 DOI: 10.5114/pg.2021.111766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Ciriza de los Ríos C, Aparicio Cabezudo M, Zatarain Vallés A, Rey E. Practical approach to irritable bowel syndrome-diarrhea beyond low-FODMAP diet. Rev Esp Enferm Dig 2022;114. [DOI: 10.17235/reed.2022.8749/2022] [Reference Citation Analysis]
|
| 76 |
Lambarth A, Zarate-Lopez N, Fayaz A. Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2022;34:e14289. [PMID: 34755926 DOI: 10.1111/nmo.14289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 77 |
Wark G, Samocha-bonet D, Ghaly S, Danta M. The role of nutrition in inflammatory bowel disease: disease associations, management of active disease and maintenance of remission. Reference Module in Food Science 2022. [DOI: 10.1016/b978-0-12-821848-8.00104-9] [Reference Citation Analysis]
|
| 78 |
Watson WT, Leblanc V. Role of foods in persistent gastrointestinal disorders: Irritable bowel syndrome and inflammatory bowel disease. Reference Module in Food Science 2022. [DOI: 10.1016/b978-0-323-96018-2.00020-1] [Reference Citation Analysis]
|
| 79 |
Müller-Lissner S, Andresen V, Corsetti M, Bustos Fernández L, Forestier S, Pace F, Valdovinos MA. Functional Abdominal Cramping Pain: Expert Practical Guidance. J Clin Gastroenterol 2022;56:844-52. [PMID: 36149666 DOI: 10.1097/MCG.0000000000001764] [Reference Citation Analysis]
|
| 80 |
Iribarren C, Maasfeh L, Öhman L, Simrén M. Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review. Gut Microb 2022;3:e7. [DOI: 10.1017/gmb.2022.6] [Reference Citation Analysis]
|
| 81 |
Gillan C. Review article: the effectiveness of group and self-help hypnotherapy for irritable bowel syndrome and the implications for improving patients' choice and access to treatment. Aliment Pharmacol Ther 2021;54:1389-404. [PMID: 34591988 DOI: 10.1111/apt.16623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 82 |
Yadav YS, Eslick GD, Talley NJ. Review article: irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders. Aliment Pharmacol Ther 2021;54 Suppl 1:S24-32. [PMID: 34927758 DOI: 10.1111/apt.16624] [Reference Citation Analysis]
|
| 83 |
Paine P. Review article: current and future treatment approaches for pain in IBS. Aliment Pharmacol Ther 2021;54 Suppl 1:S75-88. [PMID: 34927753 DOI: 10.1111/apt.16550] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 84 |
Black CJ. Review article: Diagnosis and investigation of irritable bowel syndrome. Aliment Pharmacol Ther 2021;54 Suppl 1:S33-43. [PMID: 34927756 DOI: 10.1111/apt.16597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Liu JJ, Brenner DM. Review article: current and future treatment approaches for IBS with constipation. Aliment Pharmacol Ther 2021;54 Suppl 1:S53-62. [PMID: 34927760 DOI: 10.1111/apt.16607] [Reference Citation Analysis]
|
| 86 |
Chuah KH, Mahadeva S. The challenges of implementing evidence-based therapy for irritable bowel syndrome in Asia. JGH Open 2021;5:1225-6. [PMID: 34816007 DOI: 10.1002/jgh3.12665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 87 |
Quach DT, Vu KT, Vu KV. Prevalence, clinical characteristics, and management of irritable bowel syndrome in Vietnam: A scoping review. JGH Open 2021;5:1227-1235. [DOI: 10.1002/jgh3.12616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 88 |
McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine 2021;41:101154. [PMID: 34712929 DOI: 10.1016/j.eclinm.2021.101154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 89 |
Chang L. How to Approach a Patient with Difficult-to-Treat IBS. Gastroenterology 2021;161:1092-1098.e3. [PMID: 34331916 DOI: 10.1053/j.gastro.2021.07.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 90 |
Lynch E, Troob J, Lebwohl B, Freedberg DE. Who uses probiotics and why? A survey study conducted among general gastroenterology patients. BMJ Open Gastroenterol 2021;8:e000742. [PMID: 34446439 DOI: 10.1136/bmjgast-2021-000742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 91 |
Akbani U, Vasant DH. Editorial: important insights into prescribing practices and training needs of gastroenterologists regarding use of central neuromodulators in IBS. Aliment Pharmacol Ther 2021;54:339-40. [PMID: 34236092 DOI: 10.1111/apt.16495] [Reference Citation Analysis]
|
| 92 |
Vasant DH. Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating-a step in the right direction for targeted treatment? Aliment Pharmacol Ther 2021;54:196-7. [PMID: 34170538 DOI: 10.1111/apt.16440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
